Cisplatin is the most commonly used first-line drug for cancer treatment. However, many
patients develop resistance to cisplatin therapy which ultimately results in therapy failure …

Background/Aim: A hallmark of the progression of prostate cancer to advanced disease is
the acquisition of androgen-independent growth. This malignant phenotype is characterized …

Purpose HIF1α over expression correlates with poor prognosis in a number of cancers.
Although it is widely accepted that hypoxia induces HIF1α expression up-regulation by a …

PURPOSE:: We evaluated the antitumor effects of docetaxel (Sigma®) and histone
deacetylase inhibitors in hormone refractory prostate cancer cells, and analyzed the …

Background: The hypoxia marker pimonidazole is a candidate biomarker of cancer
aggressiveness. We investigated the transcriptional programme associated with …

Hypoxia confers resistance to common cancer therapies, however, it has also has been
shown to result in genetic alterations which may allow a survival advantage and increase …

Disruption of the microtubule cytoskeleton impairs tumor angiogenesis by inhibiting the
hypoxia-inducible factor (HIF-1α) pathway. However, the signaling cascade linking …

Hypoxia frequently occurs in solid tumors and is known to contribute to chemotherapy
resistance. However, the mechanisms leading to chemotherapy resistance are not entirely …

Purpose Tumor hypoxia is a common feature of any cancer, including prostate cancer (CaP),
and associated with tumor cell aggressiveness. Although some reports are available on …

Recent studies have reported that TUBB3 overexpression is involved in docetaxel (DTX)
resistance in prostate cancer (PCa). The aim of this study was to clarify the role of TUBB3 in …